ArticleActa parasitologica2025
Therapeutic Effects of Green Synthesized Copper Nanoparticles Against Hydatid Disease Through Inhibiting Inflammation, Oxidative Stress, and Apoptosis.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The application of nanoparticles green-formulated by Lycium barbarum leaf aqueous extract in the treatment of myocardial infarction.Discover nano · 2026Article
- Recent advances in the detection and treatment of hydatid cysts by nanomaterial-based carriers.Iranian journal of basic medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to green synthesized copper nanoparticles (CNP) using Lupinus arcticus extract and assess the protoscolicidal effects and the effectiveness of these nanoparticles in experimental animal settings to combat hydatid cysts.
methodsThe protoscolicidal properties of CNP were examined in vitro on hydatid cyst PS via the eosin exclusion assay. The in vivo effectiveness of CNP at doses of 20, 40, and 80 mg/kg/day for 28 days on hydatid cyst-infected mice was determined by assessing the number, size, weight of hydatid cysts the gene expression levels of caspase-3, antioxidant (glutathione peroxidase (GPx) and superoxide dismutase (SOD)) and inflammatory cytokines (Interleukin-4 (IL-4), IL-10, and inducible nitric oxide synthase (iNOS)) in the infected mice were also assessed by Real-time PCE.
resultsAnalyses revealed that the CNP had a spherical shape, ranging in size from 10 to 85 nm. The half-maximal inhibitory concentration (IC50) values for CNP against protoscoleces ranged from 39.9 to 341.3 µg/mL. Caspase-3 gene expression in the PS treated with CNP at 1/3 IC50, ½ IC50, and IC50 was 1.79-, 3.11-, and 5.39-fold change (p < 0.001). Upon administration of CNP, particularly at doses of 80 mg/kg, a significant decrease (p < 0.001) in hydatid cysts' quantity, size, and weight was evident. CNP treatment caused a notable reduction in oxidative stress markers and inflammatory cytokines and increased the gene expression of antioxidant enzymes (p < 0.001), whereas it modulated the serum levels of liver function parameters.
conclusionThe study indicated the potential of green-synthesized CNP for eliminating the protoscoleces and in managing hydatid cysts through leveraging its antioxidant and anti-inflammatory characteristics. Nevertheless, additional investigations are necessary to elucidate the precise mechanisms of action and evaluate its effectiveness in clinical trials. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40113606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.